DUBLIN, June 28, 2016 /PRNewswire/ -- At the
12th Annual Conference of the Metabolomics Society
(www.metabolomics2016.org), Bruker announces a new, more
comprehensive, more efficient and easy-to-use profiling module for
detailed lipoprotein subclass analysis using Nuclear Magnetic
Resonance (NMR). Lipoproteins are key in assessing the risk
of cardiovascular disease (CVD). In recent years, it has
become clear that efficient and fast methods for analyzing the very
important lipoprotein subclasses provide further insights into
CVD. Current methods are time-consuming and costly, and do
not provide sufficiently detailed insights for deeper clinical
research into the diagnosis, prognosis and prevention of CVD.
![AVANCE-IVDr systems at St. Mary's Clinical Phenome Center (London, UK). AVANCE-IVDr systems at St. Mary's Clinical Phenome Center (London, UK).](https://photos.prnewswire.com/prnvar/20160627/383804)
Based on Bruker's 600 MHz AVANCE™ IVDr in
vitro diagnostics research platform, the new
B.I.-LISA (Bruker IVDr
LIpoprotein Subclass Analysis)
lipoprotein subclass module now provides a fast and cost-effective
method with great potential for in-depth clinical research in
CVD. It was developed in collaboration with Professor Nauck,
the Head of the Institute of Clinical Chemistry and Laboratory
Medicine at Greifswald University in Germany.
Professor Nauck commented: "Lipoproteins play an important
role in the body's function, and further understanding of their
subclasses brings us one step closer to understanding and possibly
preventing cardiovascular and related diseases. With Bruker's
IVDr-by-NMR profiling module B.I.-LISA, we can
extract information on the main classes of lipoproteins and more
importantly, their subclasses, in plasma. This enables clinical
researchers to investigate the associations of lipoprotein subclass
concentrations with diseases. We believe this NMR method has
great potential for identifying CVD risks in diagnostics,
individualized prognosis and personalized treatment monitoring in
the future."
Available as a new option for Bruker's IVDr-by-NMR platform,
B.I.-LISA offers significant advantages over
conventional labor-intensive methods like ultracentrifugation, and
over earlier NMR 400 MHz methods which have limited dispersion and
sensitivity, and cannot provide subclass quantification that is as
detailed and as reproducible as the latest tube-based NMR subclass
analysis methods at 600 MHz. The B.I.-LISA
module on the 600 MHz AVANCE IVDr NMR platform can
screen up to 150 samples per day in full automation. This
includes report generation of 114 lipoprotein related parameters,
simplifying the measurement procedure and providing high throughput
with highest information content. Even higher
throughput is possible, depending on accuracy and precision
requirements in diagnostics research applications.
The B.I.-LISA test fulfills the NCEP (US National
Cholesterol Education Program) requirements used worldwide in
analytical service labs for lipoprotein main fractions with regard
to precision and accuracy. B.I.-LISA determines
cholesterol, free cholesterol, phospholipids, triglycerides,
apolipoproteins A1, A2, B and particle numbers for plasma and serum
lipoprotein main and subclasses. Bruker's Standard Operating
Procedures (SOPs) support a high degree of reproducibility and
transferability from instrument to instrument – regardless of
operator expertise.
Bruker's lipoprotein subclass profiling module
B.I.-LISA is for research purpose only. For
more information, please visit www.bruker.com/IVDr
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance
scientific research instruments and high-value analytical solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, productivity and customer
success in life science molecular research, in applied and pharma
applications, in microscopy, nano-analysis and industrial
applications, as well as in cell biology, preclinical imaging,
clinical research, microbiology and molecular diagnostics.
For more information, please visit: www.bruker.com.
Media
Contact:
|
Investor
Contact:
|
Thorsten Thiel,
Ph.D.
|
Stacey
Desrochers
|
Director Marketing
and Communications
|
Bruker Investor
Relations
|
Bruker BioSpin
Group
|
Bruker
Corporation
|
T: +49 (721)
5161–6500
|
T: +1
(978)-663-3660
|
E:
thorsten.thiel@bruker.com
|
E:
stacey.desrochers@bruker.com
|
Photo - http://photos.prnewswire.com/prnh/20160627/383804
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bruker-announces-more-comprehensive-and-efficient-nmr-profiling-module-for-detailed-lipoprotein-subclass-analysis-in-cardiovascular-disease-research-300290782.html
SOURCE Bruker Corporation